• Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

  • Oct 24 2024
  • Length: 21 mins
  • Podcast

Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

  • Summary

  • Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    Show More Show Less

What listeners say about Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.